DEA

Freedom's Just Another Word For Losing 2,000 Cannabis Plants In Maine Police Raid
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Armed Robbers Make Off With $437,000 From Marijuana Courier: Cannabis Banking Reform Would Stem Cannabis Dispensary Attacks Where Workers Are Sitting Ducks
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Armed Robbers Make Off With $437,000 From Marijuana Courier: Cannabis Banking Reform Would Stem Cannabis Dispensary Attacks Where Workers Are Sitting Ducks
Anti-Cannabis Group Raises Money To Scuttle DEA Rescheduling Effort
DEA And Cannabis Rescheduling: A Rollercoaster Ride You Don't Want To Miss, But Keep Your Seatbelts On

DEA Recent News

GOP Senator Bashes Dems' Push For Marijuana Legalization As Pro-Criminal & Anti-American: 'It's Obscene'
GOP Senator Bill Hagerty accused the Democrats of pursuing policies that are pro-criminal and anti-American.
Is Cannabis Rescheduling Imminent?
Rumors of an imminent drug policy announcement swept through the industry Tuesday morning after the Associated Press reported the Drug Enforcement Administration (DEA) plans to reschedule cannabis.
Billions On The Move: Tracking Market Cap Changes In Top Cannabis Firms After DEA Rescheduling Announcement
Tuesday's announcement that the DEA is moving towards rescheduling cannabis from Schedule I to Schedule III, has already injected billions into the publicly traded market for cannabis companies.
DEA Moves To Reschedule Weed, Cannabis Stocks Go For Wild Ride, Pummel Short Sellers With $210M In Losses
Cannabis stocks soared following Tuesday's news that the DEA intends to designate marijuana from Schedule I to Schedule III.
Cannabis Advocates Say DEA's Move Represents 'Progress But Not Justice,' Ends War On Medical Marijuana Patients, But Not War On Drugs
Cannabis Stocks React To DEA Rescheduling: Canopy & Aurora Surge, Tilray, WM Tech Hold Steady
In a historic trading session on Tuesday, cannabis stocks soared following the DEA's reported decision to reclassify marijuana from Schedule I to Schedule III under the Controlled Substances Act.
Rep Blumenauer On Marijuana Reclassification: 'Legalization Is Inevitable, Biden-Harris Admin Is Listening' To The People
In a landmark decision that could reshape the landscape of American drug policy, the U.S.
DEA's Move To Reclassify Cannabis Seen As 'Significant,' But Fails To Resolve State-Federal Conflict
DEA calls for reclassification of botanical cannabis from Schedule I to III under federal law. NORML praises decision but cautions on state/federal divide.
Cannabis Stocks And ETFs Surge As DEA Moves To Reschedule Marijuana
The cannabis sector saw a notable upswing on Tuesday on news of the Drug Enforcement Administration's (DEA) historic decision to align its stance with a recommendation from the Department of Health and Human Services and move
US Cannabis Council Calls DEA Historic Decision To Reclassify Cannabis 'A Tectonic Shift'
Conklin emphasized the importance of this decision, stating, "The US Cannabis Council strongly supports the move by the DEA"
Breaking: DEA Reportedly Moves To Reschedule Cannabis, Stocks Rise Sharply On The News
The DEA plans to reclassify marijuana as a less dangerous drug with medical uses, a historic shift that could have ripple effects across the US.
Senators Warren, Fetterman Plus 18 More Dems Tell DEA 'It's Time To Act' On Cannabis Rescheduling
20 Democrats urged the DEA to deschedule marijuana and "resolve more than 50 years of failed, racially discriminatory marijuana policy."
DEA Sanctions Religious Use Of Ayahuasca But Refuses Psilocybin For Cancer Patients' Pain Relief
DEA Public Comment Period And A Cannabis-Related Crypto Bill? You Heard It First At Benzinga Conference
In Beacon Securities's latest report issued after the Benzinga Cannabis Capital Conference in Florida, analysts delved into significant developments and key conversations that are shaping the future of the cannabis industry.
Analyst Reacts To FDA Commish Comments: Medical And Recreational Cannabis Could Have Separate Regulations
FDA Commissioner Robert Califf's Thursday testimony sparked new conversations about the future of cannabis in the U.S. particularly concerning its medical and recreational classifications.
FDA Commissioner To House Committee: 'There's No Reason For DEA To Delay' Cannabis Rescheduling
FDA Commissioner Robert Califf faced questions on various critical issues at a House Oversight hearing, including the rescheduling of cannabis and FDA's decision not to regulate CBD as a food and dietary supplement.
'This Is Insanity, Someone's Got To Act,' Marijuana Researcher Files Fed Lawsuit Against DEA Over 'Unconstitutional Process'
EXCLUSIVE: DEA-Licensed Cannabis Co. Maridose To Launch Series A Funding Round At Upcoming Benzinga Conference
Maridose LLC, a company recognized for its contributions to the field of legalized medical cannabis research and product development, and one of the select few companies to have been granted a license by the U.S.
DEA Revisits Proposed Ban On Two Psychedelic Compounds: Researchers Disagree, Insist On Hearings
The Drug Enforcement Administration (DEA) is revisiting its stance on the classification of two psychedelic compounds, 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC), reported Marijuana Moment.  
DEA's Resistance To Cannabis Rescheduling Ignites Policy Clash
Growing discord between White House and DEA over rescheduling of marijuana. DEA cites unproven medical benefits and potential for abuse, in contrast to HHS findings.
DEA Comes Out Of The Shadows To Ensure Cannabis Rescheduling Process Is Not Being Done Under 'Shroud Of Secrecy'
The DEA's silence beyond acknowledging the receipt of the U.S. Department of Health and Human Services (HHS) suggestion to reclassify marijuana has been a source of frustration for advocates and legislators, including co-chairs of the Congressional Cannabis Caucus Rep. Barbara Lee (D-CA) and Rep. Earl Blumenauer, (D-OR) who have complained about the DEA's lack of transparency.
GOP Mitt Romney Pens Letter To DEA Bashing Cannabis Rescheduling, Dems' Letter To DOJ Bashes Broken Promises
All in all, it was a good day for the lost art of letter-writing.
Rep. Blumenauer Grills Fed Health Agency For Clarity On Cannabis Rescheduling As Debate Heats Up
Rep. Blumenauer seeks answers from HHS on cannabis scheduling, citing failed federal stance based on stigma, not science. Urges change and action.